<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444637</url>
  </required_header>
  <id_info>
    <org_study_id>RACE_1.0</org_study_id>
    <nct_id>NCT02444637</nct_id>
  </id_info>
  <brief_title>Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD</brief_title>
  <official_title>Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Neuroscience Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Neuroscience Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA &amp; HSA, is
      authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.

      In this trial, the investigators will be studying the effectiveness of Rivastigmine in
      subjects with AD and cerebrovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Demonstrated Benefit in Global and Cognitive Measures</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>CVA (Cerebrovascular Accident)</condition>
  <arm_group>
    <arm_group_label>Rivastigmine (Exelon) Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine</intervention_name>
    <arm_group_label>Rivastigmine (Exelon) Patch</arm_group_label>
    <other_name>Exelon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50-85 years

          -  Diagnosis of dementia of the Alzheimer's type according to the National Institute of
             Ageing-Alzheimer's Association Criteriah

          -  MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of
             recruitment demonstrating the presence of WMH of â‰¥2 on the Fazekas scale (Score range
             of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3
             indicates severe WMH).i

          -  Clinical Dementia Rating score of 1-2j

          -  Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek

          -  English or Mandarin speaking, literate participants

        Exclusion Criteria:

          -  Severe neurological, psychiatric or systemic disease which in the opinion of the
             clinician could interfere with trial assessments

          -  The use of any investigational drugs, new psychotropic or dopaminergic agents,
             cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to
             recruitment

          -  Known skin allergy or previous allergic reaction to Rivastigmine patch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jocelyn Cheong</last_name>
    <phone>(65) 63577635</phone>
    <email>ctru@nni.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Neuroscience Institute</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn Cheong</last_name>
      <phone>(65) 63577635</phone>
      <email>ctru@nni.com.sg</email>
    </contact>
    <investigator>
      <last_name>Nagaendran Kandiah, MRCP;FAMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Neuroscience Institute</investigator_affiliation>
    <investigator_full_name>Dr Nagaendran Kandiah</investigator_full_name>
    <investigator_title>Senior Consultant, Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

